Skip to main content

Table 4 Cytogenetic abnormalities of AML patients stratified by age groups

From: Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia

 Total 325Younger AML patients (n = 268)Older AML patients (n = 57)p value
Genes mutation total events (mean)2.021.942.370.034*
 TET2164 (50.5%)136 (50.7%)28 (49.1%)0.8238
 ASXL162 (19.1%)46 (17.2%)16 (28.1%)0.057#
 CEBPA56 (17.2%)49 (18.3%)7 (12.3%)0.2758
 FLT353 (16.3%)45 (16.8%)8 (14.0%)0.609
 DNMT3A44 (13.5%)35 (13.1%)9 (15.8%)0.584
 NRAS39 (12.0%)32 (11.9%)7 (12.3%)0.943
 NPM136 (11.1%)29 (10.8%)7 (12.3%)0.7498
 RUNX125 (7.7%)17 (6.3%)8 (14.0%)0.0478*
 IDH122 (6.8%)19 (7.1%)3 (5.3%)0.618
 IDH222 (6.8%)13 (4.9%)9 (15.8%)0.0028**
 KIT19 (5.8%)18 (6.7%)1 (1.8%)0.147#
 ETV69 (2.8%)7 (2.6%)2 (3.5%)0.7079
 TP539 (2.8%)4 (1.5%)5 (8.8%)0.0024**
 WT18 (2.5%)6 (2.2%)2 (3.5%)0.574
 U2AF18 (2.5%)6 (2.2%)2 (3.5%)0.574
 PHF68 (2.5%)6 (2.2%)2 (3.5%)0.574
 EZH27 (2.2%)7 (2.6%)0 (0.0%)NA
 TTN7 (2.2%)5 (1.9%)2 (3.5%)0.4378
 SF3B17 (2.2%)3 (1.1%)4 (7.0%)0.005**
 SRSF24 (1.2%)3 (1.1%)1 (1.8%)0.693
 JAK23 (0.9%)2 (0.7%)1 (1.8%)0.4698
DNA methylation (frequency, %)252 (77.5%)202 (75.4%)50 (87.7%)0.0425*
RNA spliceosome (frequency, %)20 (6.2%)12 (4.5%)8 (14.0%)0.006399**
Chromatin remodelling (frequency, %)69 (21.2%)53 (19.8%)16 (28.1%)0.164379#
Transcriptional deregulation (frequency, %)89 (27.04%)72 (26.9%)17 (28.8%)0.649175
Activated signalling (frequency, %)118 (36.3%)101 (37.7%)17 (28.8%)0.262345
  1. #Although there was difference, but no statistically significance was observed between two groups
  2. *Statistically difference (p < 0.05) was obseved between two groups
  3. **Statistically singnificant difference (p < 0.01) was obseved between two groups